{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:20:43Z","timestamp":1782249643727,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To report the 60-month safety and effectiveness results of a multicenter, prospective, randomized controlled trial comparing the ZILVER PTX paclitaxel-eluting stent to prosthetic above-the-knee bypass for the treatment of symptomatic TransAtlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Patients were enrolled between October 2013 and July 2017. One of the secondary outcomes was primary patency at 60\u00a0months, defined as no evidence of binary restenosis or occlusion within the target lesion or bypass graft based on a duplex ultrasound peak systolic velocity ratio\u2009&lt;\u20092.4 and no clinically-driven target lesion revascularization (TLR) in endovascular cases or reintervention to restore flow in the bypass at 60\u00a0months. Survival rates after 5\u00a0years were also analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>220 patients (mean age 68.6\u2009\u00b1\u200910.5\u00a0years; 159 men) were included and randomized to ZILVER PTX (n\u2009=\u2009113, 51.40%) or BYPASS group (n\u2009=\u2009107, 48.60%). The 60-month primary patency rate was 49.3% for the ZILVER PTX group versus 40.7% for the bypass group (<jats:italic>p<\/jats:italic>\u2009=\u20090.6915). Freedom from TLR was 63.8% for the ZILVER PTX group versus 52.8% for the bypass group (<jats:italic>p<\/jats:italic>\u2009=\u20090.2637). At 5\u00a0years, no significant difference in survival rate could be seen between the ZILVER PTX and the bypass group (69.1% vs. 71% respectively, <jats:italic>p<\/jats:italic>\u2009=\u20090.5503).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Even at 5\u00a0years, non-inferior safety and effectiveness results of the ZILVER PTX could be seen. These findings confirmed that the use of ZILVER PTX stents can be considered as a valid alternative for bypass surgery when treating long and complex femoropopliteal lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00270-023-03549-0","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T17:01:42Z","timestamp":1693933302000},"page":"1348-1358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results"],"prefix":"10.1007","volume":"46","author":[{"given":"Michel J.","family":"Bosiers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"De Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Torsello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Galvagni","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dierk","family":"Scheinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Veroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Maene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Keirse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulio","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Henning","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Te\u03b2arek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Giaquinta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"van den Eynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Verbist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joren","family":"Callaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Deloose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bosiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"3549_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FG Fowkes","year":"2013","unstructured":"Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(13)61249-0.","journal-title":"Lancet"},{"issue":"suppl S","key":"3549_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45","author":"L Norgren","year":"2007","unstructured":"Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5\u201367.","journal-title":"J Vasc Surg"},{"issue":"9","key":"3549_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, et al. ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J. 2018;39(9):763\u2013816.","journal-title":"Eur Heart J"},{"key":"3549_CR4","unstructured":"Bosiers M, Peeters P, Tessarek J, Zilver PTX Single-Arm Study Investigators, et al. The Zilver PTX Single Arm Study: 12-month results from the TASC C\/D lesion subgroup. J Cardiovasc Surg (Torino). 2013;54(1):115\u2013122."},{"issue":"3","key":"3549_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jcin.2015.09.035","volume":"9","author":"H Yokoi","year":"2016","unstructured":"Yokoi H, Ohki T, Kichikawa K, et al. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 12-month results. JACC Cardiovasc Interv. 2016;9(3):271\u20137.","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"3549_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1526602820902014","volume":"27","author":"M Bosiers","year":"2020","unstructured":"Bosiers M, Settaci C, De Donato G, et al. ZILVERPASS study: ZILVER PTX Stent vs bypass surgery in femoropopliteal lesions. J Endovasc Ther. 2020;27(2):287\u201395.","journal-title":"J Endovasc Ther"},{"key":"3549_CR7","doi-asserted-by":"publisher","unstructured":"Bosiers M, De Donato G, Torsello G, et al. ZILVERPASS study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal lesions. J Cardiovasc Surg. 2023. https:\/\/doi.org\/10.23736\/S0021-9509.23.12607-3.","DOI":"10.23736\/S0021-9509.23.12607-3"},{"key":"3549_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1067\/mva.2000.103238","volume":"31","author":"RM Green","year":"2000","unstructured":"Green RM, Abbott WM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg. 2000;31:417\u201325.","journal-title":"J Vasc Surg"},{"issue":"4","key":"3549_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ejvs.2004.12.023","volume":"29","author":"J Berglund","year":"2005","unstructured":"Berglund J, Bj\u00f6rck M, Elfstr\u00f6m J. Long-term results of above knee femoropopliteal bypass depend on indication for surgery and graft-material. Eur J Vasc Endovasc Surg. 2005;29(4):412\u20138.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"3549_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejvs.2007.01.016","volume":"34","author":"LP Jensen","year":"2007","unstructured":"Jensen LP, Lep\u00e4ntalo M, Fossdal JE, et al. Dacron or PTFE for above-knee femoropopliteal bypass. A multicenter randomised study. Eur J Vasc Endovasc Surg. 2007;34(1):44\u20139.","journal-title":"Eur J Vasc Endovasc Surg."},{"key":"3549_CR11","doi-asserted-by":"crossref","unstructured":"Midy D, Papon X, Patra P, Association Universitaire de Recherche en Chirurgie Vasculaire (AURC), et al. Randomized study of noninferiority comparing prosthetic and autologous vein above-knee femoropopliteal bypasses. Ann Vasc Surg. 2016;31:99\u2013104.","DOI":"10.1016\/j.avsg.2015.07.047"},{"issue":"15","key":"3549_CR12","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","volume":"133","author":"MD Dake","year":"2016","unstructured":"Dake MD, Ansel GM, Jaff MR, Zilver PTX Investigators, et al. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial. Circulation. 2016;133(15):1472\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016900. (discussion 1483).","journal-title":"Circulation."},{"key":"3549_CR13","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa2207899","volume":"387","author":"A Farber","year":"2022","unstructured":"Farber A, Menard MT, Conte MS, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med. 2022;387:2305\u201316.","journal-title":"N Engl J Med"},{"key":"3549_CR14","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/S0140-6736(23)00462-2","volume":"401","author":"AW Bradbury","year":"2023","unstructured":"Bradbury AW, Moakes CA, Popplewell M, et al. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet. 2023;401:1798\u2013809.","journal-title":"Lancet"},{"key":"3549_CR15","doi-asserted-by":"publisher","first-page":"170853812211247","DOI":"10.1177\/17085381221124701","volume":"6","author":"RJ Vossen","year":"2022","unstructured":"Vossen RJ, Fokkema TM, Vahl AC, et al. Systematic review and meta-analysis comparing the autogenous vein bypass versus a prosthetic graft for above-the-knee femoropopliteal bypass surgery in patients with intermittent claudication. Vascular. 2022;6:17085381221124700. https:\/\/doi.org\/10.1177\/17085381221124701.","journal-title":"Vascular"},{"issue":"24","key":"3549_CR16","doi-asserted-by":"publisher","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","volume":"7","author":"K Katsanos","year":"2018","unstructured":"Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245. https:\/\/doi.org\/10.1161\/JAHA.118.011245.","journal-title":"J Am Heart Assoc"},{"key":"3549_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-023-03507-w","author":"S M\u00fcller-H\u00fclsbeck","year":"2023","unstructured":"M\u00fcller-H\u00fclsbeck S, Fanelli F, Haage P, et al. Re-analysis of old data and new outcomes data do not support a link between paclitaxel coated balloons and paclitaxel eluting stents and mortality: these devices should be used in PAD (peripheral arterial disease) treatment in femoropopliteal disease on the basis of their published efficacy. Cardiovasc Intervent Radiol. 2023. https:\/\/doi.org\/10.1007\/s00270-023-03507-w.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3549_CR18","unstructured":"UPDATE: Paclitaxel-Coated Devices to Treat Peripheral Arterial Disease Unlikely to Increase Risk of Mortality - Letter to Health Care Providers | FDA. https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-023-03549-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T16:03:57Z","timestamp":1696349037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-023-03549-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3549"],"URL":"https:\/\/doi.org\/10.1007\/s00270-023-03549-0","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: Michel J. Bosiers is a consultant for Cook Medical, Pierre Galvagni Silveira received research, clinical trial, or drug study funds from Cook Medical. Giovanni Torsello received research grants from Cook Medical. Koen Deloose is a clinical trial investigator, consultant, and lecturer for Cook Medical. Dierk Scheinert is a consultant for Cook Medical. Tulio Navarro received research grants from Cook Medical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Consent for publication was obtained for every individual person\u2019s data included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}